Lee Jongsun, Kim Sung-Ryeol, Park Jong Han, Park Kyung-Hee, Jeong Kyoung Yong, Lee Jae-Hyun, Kang Chon-Sik, Kim Kyeong-Hoon, Park Jung-Won
Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Allergy Asthma Immunol Res. 2022 Jul;14(4):379-392. doi: 10.4168/aair.2022.14.4.379.
ω-5 gliadin is the major allergen that causes wheat-dependent exercise-induced anaphylaxis (WDEIA). Recently, a missing mutant wheat cultivar at 1B chromosome and closely linked was bred. This cultivar (ω5D) has a deficiency in ω-5 and γ-gliadins as well as some low-molecular-weight glutenins. We evaluated specific immunoglobulin E (sIgE) reactivity of the ω5D in WDEIA patients compared to wild-type cultivar.
Serum samples from 14 WDEIA and 7 classic wheat allergy patients were used to compare the allergenicity of ω5D and wild-type cultivars using immunoglobulin E immunoblotting, enzyme-linked immunosorbent assay (ELISA), and ImmunoCAP inhibition assays.
Immunoblotting revealed that ω5D extracts had less sIgE binding to gliadins and glutenins in WDEIA sera than wild-type extracts. Immunoblot inhibition assay for gliadin sIgE reactivity also showed that ω5D gliadins had less allergenicity than wild-type gliadins. ELISA inhibition assay showed stronger allergenicity of gliadins than glutenins, although they had cross-reactivity. This assay also showed that the 50% inhibitory concentrations (IC50) of ω5D extracts against gliadin- or glutenin-sIgE reactivity were approximately 4-fold higher in WDEIA patients than those of wild-type extracts. The inhibition capacity of ω5D gliadins against recombinant ω-5 gliadin-sIgE reactivity was also lower in WDEIA patients than that of wild-type.
The allergenicity of the ω5D cultivar is markedly lower for WDEIA patients in the sIgE inhibition tests. These results suggest that the ω5D cultivar may be a safe alternative for WDEIA patients.
ω-5麦醇溶蛋白是导致小麦依赖运动诱发过敏反应(WDEIA)的主要过敏原。最近,培育出了一种在1B染色体上缺失突变且紧密连锁的小麦品种。该品种(ω5D)缺乏ω-5和γ-麦醇溶蛋白以及一些低分子量谷蛋白。我们评估了与野生型品种相比,ω5D在WDEIA患者中的特异性免疫球蛋白E(sIgE)反应性。
使用14例WDEIA患者和7例经典小麦过敏患者的血清样本,通过免疫球蛋白E免疫印迹法、酶联免疫吸附测定(ELISA)和免疫捕获抑制试验,比较ω5D和野生型品种的致敏性。
免疫印迹显示,与野生型提取物相比,ω5D提取物与WDEIA血清中的麦醇溶蛋白和谷蛋白的sIgE结合较少。麦醇溶蛋白sIgE反应性的免疫印迹抑制试验也表明,ω5D麦醇溶蛋白的致敏性低于野生型麦醇溶蛋白。ELISA抑制试验显示,尽管麦醇溶蛋白和谷蛋白有交叉反应,但麦醇溶蛋白的致敏性更强。该试验还表明,ω5D提取物对麦醇溶蛋白或谷蛋白sIgE反应性的50%抑制浓度(IC50)在WDEIA患者中比野生型提取物高约4倍。在WDEIA患者中,ω5D麦醇溶蛋白对重组ω-5麦醇溶蛋白sIgE反应性的抑制能力也低于野生型。
在sIgE抑制试验中,ω5D品种对WDEIA患者的致敏性明显较低。这些结果表明,ω5D品种可能是WDEIA患者的安全替代品。